COEGIN — Coegin Pharma AB Balance Sheet
0.000.00%
Last trade - 00:00
- SEK108.54m
- SEK102.99m
2019 December 31st | 2020 December 31st | R2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | Interim Report | ARS | ARS |
Standards: | SAS | SAS | — | SAS | SAS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 19.5 | 16.6 | 25.7 | 3.82 | 5.55 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 5.71 | 2.35 | 4.5 | 2.75 | 0.499 |
Prepaid Expenses | |||||
Total Current Assets | 25.2 | 19.1 | 30.3 | 6.97 | 6.21 |
Net Property, Plant And Equipment | — | 0.002 | 0.002 | 0.485 | 0.302 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Total Assets | 25.2 | 19.1 | 30.3 | 29.2 | 15.4 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 0.963 | 2.43 | 10.3 | 8.23 | 8.68 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Liabilities | 0.963 | 2.43 | 10.3 | 8.23 | 8.68 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 24.2 | 16.7 | 20.1 | 21 | 6.75 |
Total Liabilities & Shareholders' Equity | 25.2 | 19.1 | 30.3 | 29.2 | 15.4 |
Total Common Shares Outstanding |